Raise Series D · $350.7M · announced Feb 26, 2025 Company release ↗Source quote
Feb 26, 2025 · Company release ↗ “– Eikon Therapeutics, Inc., a pivotal-stage biotechnology company that integrates advanced engineering with cutting-edge molecular and cell biology to accelerate drug discovery and development, today announced the initial closing of a $350.7 million Series D financing”
Raises announced in these releases: $350.7M disclosed.
Trial start Phase 2/Phase 3: A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. source ↗
Raise IPO: $381M (total, as published), announced Feb 5, 2026. Source: company's own press page. source ↗
Trial start Phase 1/Phase 2: EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors source ↗
Trial start Phase 2/Phase 3: Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. source ↗
Trial start Phase 1/Phase 2: A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. source ↗
Raise Private equity round — Series D: $350.7M (total, as published), announced Feb 26, 2025. Source: company's own press page. source ↗
Trial start 2: A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC source ↗
Trial start Phase 1/Phase 2: A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors source ↗
Trial start Phase 2: BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors source ↗
Trial start Phase 1: Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors source ↗
Trial start Phase 1: BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab source ↗
Trial start Phase 1: BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab source ↗
Upcoming milestones
2026-12 (ESTIMATED) · 2 · A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC · NCT06246110
Jun 1, 2027 (ESTIMATED) · Phase 1/Phase 2 · A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors · NCT06253130
2028-12 (ESTIMATED) · Phase 1/Phase 2 · A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. · NCT06907043
2029-03 (ESTIMATED) · Phase 1/Phase 2 · EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Micros · NCT07262619
2035-12 (ESTIMATED) · Phase 2/Phase 3 · Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. · NCT06697301
Dec 31, 2035 (ESTIMATED) · Phase 2/Phase 3 · A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. · NCT07365319
Estimated primary completion per ClinicalTrials.gov. Dates move.
Funding
Raised: $731.7M. Last 2 years.
IPO: $381M (total, as published), announced Feb 5, 2026. Source: company's own press page. source ↗
Private equity round — Series D: $350.7M (total, as published), announced Feb 26, 2025. Source: company's own press page. source ↗
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
